ALK and lung adenocarcinoma: In fact, EV-RNA profiling reveals that miR-21-5p, miR-486-3p, lncRNAs MEG3, and XIST are differentially expressed in the EVs secreted by the resistant subclones, and the circulating levels of these EV-associated miRNAs correlate with disease progression of EML4-ALK-translocated lung adenocarcinoma patients treated with ALK-TKIs [96].